Skip Navigation

Awards and Honors

  • William G. Kaelin Jr., MD, and Laurie H. Glimcher, MD, holding Kaelin's Nobel Prize and Certificate
  • A selection of awards recently earned by Dana-Farber and our staff

    November 2019 - January 2020

    The Institute

    Dana-Farber Cancer Institute was named one the most noteworthy companies and non-profits led by women in MA. Laurie H. Glimcher, MD, President and CEO is #7 on the 2019 Top 100 Women-Led Business in Massachusetts by the Commonwealth Institute and the Boston Globe Magazine. The list, created by The Commonwealth Institute – a non-profit that supports female business leaders – examined revenue, operating budget, and other variables, including number of fulltime employees in Massachusetts, workplace and management diversity, and innovative projects.

    Dana-Farber was recognized by the Human Rights Campaign as an LGBTQ Health Care Equality Top Performer in its annual Healthcare Equality Index (HEI). The HEI is recognized as the national benchmarking tool for evaluating the policies and practices of health care facilities as related to the equity and inclusion of their LGBTQ patients, visitors, and employees.

    The Worksite Wellness Council of Massachusetts named Dana-Farber a Gold Award winner for the third consecutive year in its annual WorkWell Massachusetts Awards program. The program recognizes the state’s employers of all sizes for their exemplary work in worksite health promotion and showcases their employee wellness programs’ performance.

    Boston Magazine has named more than 110 Dana-Farber-affiliated physicians and surgeons to its annual "Top Doctors" guide. Drawing from a Castle Connolly Medical Ltd. physician database, the list consists of hundreds of Boston-area physicians from many medical specialties.


    Twenty-four Dana-Farber researchers have been named as Highly Cited Researchers, according to the Highly Cited Researchers 2019 list from the Web of Science Group. The following Dana-Farber faculty are on the list: Kenneth C. Anderson, MD; Philippe Armand, MD, PhD; Toni K. Choueiri, MD; Judy E. Garber, MD, MPH; Anita Giobbie-Hurder, MS; Nathanael S. Gray, PhD; William C. Hahn, MD, PhD; Stephen Hodi, MD; Rafael A. Irizarry, PhD; Anthony Letai, MD, PhD; Heng Li, PhD; Shirley Liu, PhD; Donna Neuberg, ScD; Patrick A. Ott, MD, PhD; Kornelia Polyak, MD, PhD; Paul G. Richardson, MD; Jerome Ritz, MD; Chris Sander, PhD; Geoffrey I. Shapiro, MD, PhD; Margaret A. Shipp, MD; Richard M. Stone, MD; Marc Vidal, PhD; Patrick Y. Wen, MD; Eric P. Winer, MD.

    Suneet Agarwal, MD, PhD, co-program leader of the Stem Cell Transplant Center at Dana-Farber/ Boston Children’s Cancer and Blood Disorders Center and an assistant professor at Harvard Medical School, has been awarded the 2019 Excellence in Medicine Award by Team Telomere. Team Telomere is a nonprofit organization dedicated to providing information and support to those affected by DKC and telomere biology disorders.

    The Center for Cancer Genomics (CCG) has awarded grants of $75,000 to Andrew Aguirre, MD, PhD, and Srinivas Viswanathan, MD, PhD, respectively, for genomics-related research. The awards encourage collaborations among CCG investigators and faculty of Dana-Farber, Brigham and Women’s Hospital, and Boston Children’s Hospital, for projects having broad implications in translational oncology or precision medicine. Aguirre’s focus will be on using a single-cell RNA sequencing method to predict the effectiveness of drugs within hours from the time of a patient’s biopsy. Viswanathan will use his funding to investigate a rare and very aggressive disease known as translocation kidney cancer – a form of non-clear cell kidney cancer that makes up only 1-5% of all kidney cancers often affecting young adult patients.

    Judith Agudo, PhD, was recently awarded a Career Catalyst Research Grant from Susan G. Komen®. Agudo will use the $450,000 grant to investigate ways to use the immune system to attack breast cancer cells that have spread to the lungs. The goal is to develop an immunotherapy to target and eliminate breast metastases.

    Six Dana-Farber researchers were awarded Career Development Program (CDP) grants from the Leukemia and Lymphoma Society (LLS). The grants support promising early-career researchers who focus on understanding and treating blood cancers and relevant premalignant conditions. Dana-Farber CDP grant award winners are: Anat Biran, PhD; Juliette Bouyssou, PhD; Sondra Downey-Kopyscinski, PhD; Annamaria Gulla, MD; Shan Lin, PhD; and Gongwei Wu, PhD.

    Myles Brown, MD, is the recipient of the 2019 American Association for Cancer Research Distinguished Lectureship in Breast Cancer Research Award, supported by Aflac Inc. He received the honor at the 2019 San Antonio Breast Cancer Symposium. Brown, the Emil Frei III Professor of Medicine at Dana-Farber and Harvard Medical School, was recognized for his pioneering research involving steroid hormone receptors, which has put a spotlight on the dynamic ability of these proteins to regulate the genome.

    Steven DuBois, MD, director of Experimental Therapeutics at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, senior physician in Pediatric Oncology, and associate professor at Harvard Medical School, has received funding from TeamConnor Childhood Cancer Foundation and the Cookies for Kids’ Cancer organization. The funding will support a clinical trial for ALRN-6924, a drug that blocks certain proteins in tumor cells called MDM2 and MDMX which may be important to the growth of some cancers.

    Benjamin L. Ebert, MD, PhD, chair of the Department of Medical Oncology and the George P. Canellos, MD, and Jean S. Canellos Professor of Medicine, recently received the Meyenburg Stiftung Cancer Research Prize in Germany for his outstanding research on the pathogenesis and treatment of leukemia. Ebert’s laboratory is known for the identification of genetic mutations in blood and bone marrow cells that predispose older people to developing leukemia and for elucidation of the mechanism of action of thalidomide and its derivatives.

    Alexander A. Gimelbrant, PhD, of Chemical Biology, and assistant professor of genetics at Harvard Medical School, is among one of six pairs named to the Pew Charitable Trusts’ 2019 class of Innovation Fund investigators. His lab focuses on the function of cell identity based on allele-specific gene expression.

    Shahrzad Giudici, BSN, RN, received the DAISY Award, a quarterly honor given to an extraordinary member of the nursing department.

    Nathanael Gray, PhD, the Nancy-Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology at Dana-Farber Cancer Institute and Harvard Medical School, is one of three researchers awarded the 2019 Paul Marks Prize for Cancer Research by Memorial Sloan Kettering Cancer Center (MSK). The award recognizes promising scientists for their accomplishments in the area of cancer research. All recipients must be age 45 or younger at the time of their nomination.

    Alejandro Gutierrez, MD, has been recognized with the Milagros para Niños Award for his contributions to improving care for children with cancer, research targeting drug-resistant cancers, and work in Latin America. He received the award at the Milagros para Niños Gala, where the organization celebrated its 10th anniversary.

    Daphne A. Haas-Kogan, MD, and Catherine J. Wu, MD, have been elected to the 2019 National Academy of Medicine (NAM) for their outstanding professional achievement and commitment to service. It is considered one of the highest honors in the health and medicine fields. Haas-Kogan is a professor of radiation oncology at Harvard Medical School (HMS) and chair of the Department of Radiation Oncology at Dana-Farber and Brigham and Women’s Hospital. Wu is a professor of medicine at HMS and chief of Dana-Farber’s Division of Stem Cell Transplantation and Cellular Therapies.

    Dana-Farber Cancer Institute’s Heng Li, PhD, Assistant Professor of Biostatistics and Computational Biology in the Department of Data Sciences, will receive funding from the Chan Zuckerberg Initiative (CZI) to support open source software projects that are essential to biomedical research. CZI’s Essential Open Source Software for Science program, announced $5 million in funding for these grants to support software maintenance, growth, development, and community engagement for over 40 critical open source tools.

    Robert Knoerl, PhD, RN, an instructor in Medicine and nurse scientist in Dana-Farber’s Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, has been awarded the 2020 Oncology Nursing Society’s (ONS) Victoria Mock New Investigator Award. This award recognizes the contributions of new investigators in building a scientific foundation for oncology nursing practice.

    Nikhil Munshi, MD, director of Basic and Correlative Science, and associate director of the Jerome Lipper Multiple Myeloma Center, has been named president of the International Myeloma Society (IMS). The appointment, announced during the 17th International Myeloma Workshop in Boston, runs for two consecutive two-year terms.

    Erin Parry, MD, PhD, of the Department of Medical Oncology, is one of nine physician scientists selected by the Doris Duke Charitable Foundation to be awarded its Physician Scientist Fellowship in its inaugural year. Parry was recognized for her project entitled, “Dissecting the Mechanisms Underlying Response and Resistance to Immune Checkpoint Blockade in Richter’s Transformation.”

    Kornelia Polyak, MD, PhD, of Dana-Farber Cancer Institute has been named a 2019 Fellow of the American Association for the Advancement of Science (AAAS). Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers.

    Grant Rowe, MD, PhD, received the David B. Frohnmayer Early Investigator Award from the Fanconi Anemia Research Fund during its Scientific Symposium. Rowe, a physician in Pediatric Hematology/Oncology at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and an instructor of medicine at Harvard Medical School, will use the funding to model the hematopoietic clonal evolution in Fanconi anemia (FA).

    Clare Sullivan, BSN, MPH, clinical program manager, Patient Education, was named chair-elect of the Cancer Patient Education Network (CPEN). Renee Siegel, MSW, LCSW, program manager, Patient and Family Advisory Councils, was elected member-at-large. CPEN is a group of health care professionals who share experiences and best practices in all aspects of cancer patient education.

    Myra Tamba, BSN, RN, formerly of Dana-Farber/Brigham and Women’s Cancer Center at Milford Regional Medical Center and now on Dana-Farber’s Longwood campus, received the DAISY Award, a quarterly honor given to an extraordinary member of the nursing department.

    Deborah Toffler, MSW, LCSW, received the (Up) Beat Cancer Award at the 12th annual gala, presented by the Joe Andruzzi Foundation (JAF). Each year the award is given to an individual whose work best represents JAF’s mission: providing help, hope, and a reason to smile for cancer patients and their families by contributing financial support when it is needed most.

    With a $4.3 million grant from the federal Cancer Moonshot program, a team of Dana-Farber investigators has launched an effort to understand why immunotherapy drugs, which are dramatically effective in some cases of advanced head and neck cancer, fail to work in some patients. The multidisciplinary team, led by principal investigator Ravindra Uppaluri, MD, PhD, is using an array of cutting-edge methods to probe immunotherapy resistance in head and neck tumors – aiming to improve the drugs’ rate of response. Uppaluri, director of surgical oncology in the head and neck program, is working with co-investigators Robert Haddad, MD, chief of head and neck oncology at Dana-Farber, and David Barbie, MD, associate director, Belfer Center for Applied Cancer Science.

    October 2019


    William G. Kaelin Jr., MD, won the 2019 Nobel Prize for Medicine. Kaelin, along with Sir Peter Ratcliffe, FRS, FMedSci, of the University of Oxford, and Gregg Semenza, MD, PhD, of Johns Hopkins University, was awarded the prize for their discoveries of the molecular system by which cells sense and adapt to varying levels of oxygen availability.

    Laurie H. Glimcher, MD, president and CEO of Dana-Farber, received the Distinguished Investigator award from the Massachusetts Society for Medical Research at Massachusetts' annual Biomedical Research Day meeting and luncheon.

    July – September 2019

    The Institute

    Dana-Farber has been awarded Magnet® status from the American Nurses Credentialing Center (ANCC) for the fourth consecutive time. This prestigious designation recognizes excellence in nursing practice and health care delivery and has been awarded to only 8% of hospitals in the United States. In 2005, Dana-Farber became the first cancer center in New England to receive Magnet status. There are only five other Massachusetts hospitals who have held Magnet status for this length of time.

    The Dana-Farber Inpatient Hospital, located on floors 6B-C-D of Brigham and Women’s Hospital, was recognized with the first team DAISY Award, a quarterly honor given to an extraordinary member of the nursing department.

    Dana-Farber has received a $5 million gift from the Edward P. Evans Foundation to create a Center for Myelodysplastic Syndromes (MDS), which will focus on treating, preventing, and ultimately curing the blood disorders.

    Dana-Farber/Brigham and Women's Cancer Center has been ranked by U.S. News & World Report as the best for cancer care in New England for the 19th straight year. This year, Dana-Farber/Brigham and Women's Cancer Center is ranked #5 in the nation.


    Giada Bianchi, MD, and Zuzana Tothova, MD, PhD, of Medical Oncology, are recipients of the Doris Duke Charitable Foundation Clinical Scientist Development Award, which provides grants to physician-scientists pursuing independent clinical research careers.

    Six Dana-Farber faculty members receive Career Development Program (CDP) grants from The Leukemia & Lymphoma Society (LLS): Anat Biran, PhD; Juliette Bouyssou, PhD; Sondra Downey-Kopyscinski, PhD; Annamaria Gulla, MD; Shan Lin, PhD; and Gongwei Wu, PhD. Career Development Program (CDP) grants support researchers early in their careers. The funding supports researchers at different stages of their career, from those with less than two years of postdoctoral research to those who hold independent faculty-level positions. The grants are designed to encourage these promising young investigators to embark on academic careers involving clinical or fundamental research in the blood cancers.

    David A. Braun, MD, PhD, the John R. Svenson Fellow in Oncology at Dana-Farber/Brigham and Women’s Hospital, has been recognized by HemOnc Today as a Next Gen Innovator. The honor is presented to early-career hematologists and oncologists who have advanced their field through innovative approaches in clinical and research settings. Braun’s research focuses on understanding and improving immunotherapies in kidney cancer.

    Dipanjan Chowdhury, PhD, chief of the Division of Radiation and Genomic Stability in the Department of Radiation Oncology; Alan D’Andrea, MD, director of the Susan F. Smith Center for Women’s Cancers and of the Center for DNA Damage and Repair in the Department of Radiation Oncology; and Panos Konstantinopoulos, MD, PhD, director of translational research, Gynecologic Oncology, and associates at the University of Texas and the University of Pennsylvania have received a four-year, $3.75 million Team Science Grant from the Gray Foundation. The researchers will use the funding to study the cascade of changes that occur within cells when a key mechanism for repairing damaged DNA breaks down. The grant, announced following a national competition, is one of the first to be awarded by the Gray Foundation’s Basser Initiative, which fosters research in cancers linked to mutations or malfunctions in the BRCA gene pathways.

    Six Dana-Farber researchers have been named to receive Outstanding Investigator awards from the National Cancer Institute (NCI), adding to the Institute’s strong showing in competition for the grants. The R35 Outstanding Investigator Awards, established in 2014, provide extended grant support to investigators with outstanding records of productivity in cancer research. The newest Dana-Farber recipients are James DeCaprio, MD; Michael Eck, MD, PhD; Anthony Letai, MD, PhD; David Livingston, MD; Thomas Roberts, PhD, and David Weinstock, MD. With the addition of these recipients, Dana-Farber now holds more NCI Outstanding Investigator awards than any other single institution.

    Laurie H. Glimcher, MD, president and CEO of Dana-Farber, was named to Modern Healthcare’s list of “50 Most Influential Clinical Executives.” The program recognizes physicians in the health care industry who are deemed by their peers, and by an expert panel, the most influential in terms of demonstrating leadership and impact.

    Philip J. Kranzusch, PhD, assistant professor of Microbiology at Harvard Medical School and Dana-Farber, was named a Pew Scholar in the Biomedical Sciences. Those selected to join the Pew Scholars Program receive four years of funding to invest in exploratory research to advance human health and address some of the most challenging questions in biomedicine. Kranzusch will investigate how small RNA molecules can activate an immune response to pathogens for cancer.

    Cindy Mackenzie, a locksmith at Dana-Farber and member of the Operating Engineers Union (877), was recently named a Pride Legacy Leader over 50 by Business Equality Network magazine. Mackenzie was initially hired in 1990 as a temporary employee. She’s now been at the Institute for almost three decades. Business Equality Magazine is committed to reaching and empowering LGBTQ+, women, minority, and other underrepresented, underserved, and underutilized business communities. Its Legacy Leaders over 50 list was created to honor courageous, brilliant, and creative people who have built the foundation of the LGBTQ+ community and its culture.

    Matthew G. Oser, MD, PhD, of Medical Oncology, is a recipient of the Damon Runyon Clinical Investigator Award. The award, which is funded by the Damon Runyon Cancer Research Foundation, supports independent physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. Oser’s research focuses on developing targeted therapies for small cell lung cancer (SCLC) .

    Max Pimkin, MD, PhD, of the Pediatric Stem Cell Transplant program is one of two nationwide recipients of a 2019 Research Grant from the WES (When Everyone Survives) Foundation for leukemia (and other blood related diseases) research, as well as the recipient of an Emerging Scientist Award from the Children’s Cancer Research Fund, for his proposal entitled: Transcriptional Addiction in Acute Myloid Leukemia (AML).

    Rinaa Punglia, MD, MPH, and Daphne Haas-Kogan, MD, Dana-Farber/Brigham and Women’s Cancer Center radiation oncologists, were awarded ASTRO Fellow (FASTRO) designation by the American Society for Radiation Oncology. ASTRO Fellows program recognizes individuals who have made significant contributions to the field of radiation oncology and to the Society through research, education, patient care and service to the field. Since its inception in 2006, the FASTRO designation has been awarded to just 353 of ASTRO’s more than 10,000 members worldwide.

    Patrick Y. Wen, MD, director of the Center for Neuro-Oncology, received the 2019 Victor Levin Award for Neuro-Oncology Research. Presented by the Society for Neuro-Oncology (SNO), the award is SNO’s highest honor and recognizes individuals with a career commitment to neuro-oncology, demonstrate leadership, and have made extraordinary achievements in the field.

    Jamie White, BSN, RN, of Dana-Farber/Brigham and Women’s Cancer Center at Milford Regional Medical Center, received an individual DAISY award for nursing excellence. The DAISY Foundation (Diseases Attacking the Immune System) established the award in memory of J. Patrick Barnes, whose parents created the foundation in Patrick’s memory after experiencing firsthand the skills, care, and compassion of nurses.

    Edmond M. Chan, MD, is a recipient of the Damon Runyon Physician-Scientist Training Award. The award is given to physicians with novel approaches to fighting cancer, and who show initiative and a commitment to finding new cures.

    Paula François, MBA, a financial analyst in Nursing and Patient Care Services, recently graduated from Babson College’s master’s program with a business administration degree (MBA) and a significant accolade. She was awarded the Dr. John D. Attaway Pioneer Award, named in honor of the first person of color to graduate from Babson with a master’s degree in 1954. The award recognizes recipients for their scholarship, leadership, and service to the Babson community.

    Christopher Sweeney, MBBA, presented findings from the ENZAMET trial during the American Society of Clinical Oncology (ASCO) plenary session, where four studies considered to have the greatest potential influence on patient care are featured, out of more than 6,000 featured abstracts. This was Sweeney’s second time on the plenary stage in five years, making him one of very few presenters in ASCO’s history to have that honor twice.

    Zuzana Tothova, MD, PhD, has been recognized with four recent awards supporting her research in blood cancers:

    • She received a Tito Bastianello Young Investigator Award at the MDS 2019 International Symposium in Copenhagen, Denmark. The 10,000-euro award recognized Tothova’s work on mechanisms of cohesin mutations in myelodysplastic syndromes.
    • She was elected as one of the 2019 Forbeck Scholars by the William Guy Forbeck Research Foundation. She was recognized in the field of leukemia stem cells, heterogeneity, and metabolism – new directions for AML therapy.
    • Tothova received an inaugural RUNX1 Early Career investigator award from the RUNX1 Research Program and Alex’s Lemonade Stand. Her grant will support her research on why secondary mutations in STAG2 help pre-leukemic RUNX1-mutant blood cells in patients with familial platelet disorder (FPD) progress to leukemia.
    • Her fourth award was a discovery research grant from the Edward P. Evans Foundation to support her work on targeting DNA damage repair in cohesin-mutant MDS.

    April – June 2019

    The Institute

    U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the nation’s No. 1 pediatric cancer program in its Best Children’s Hospitals report. This marks the fifth time since the inception of U.S. News’ pediatric specialty rankings in 2009 that Dana-Farber/Boston Children’s has topped the pediatric cancer rankings. No other program has ranked No. 1 more than twice.

    A $20 million gift from the Saverin Family will establish the Saverin Breast Cancer Research Fund at Dana-Farber under the direction of Eric Winer, MD. The Saverin Family’s commitment is the largest individual gift for breast cancer research in Dana-Farber’s history and the family’s first major gift to the Institute. The sole purpose of the gift is to support research into treatment and eventual cures of advanced or stage IV metastatic breast cancer.

    This summer, Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) will implement a new ambulatory transplant program designed to help some stem cell transplant patients avoid hospital stays. Patients who qualify for the program meet key eligibility criteria and are scheduled to receive a reduced-intensity allogeneic transplant – also known as a “mini transplant.” This modified form uses lower, less toxic doses of chemotherapy and does not require radiation therapy.


    Laurie H. Glimcher, MD, president and CEO of Dana-Farber, was elected to membership of the American Philosophical Society (APS). The APS was founded in 1743 by Benjamin Franklin for the purpose of “promoting useful knowledge” and is the oldest learned society in the United States. The APS supports research and discovery through grants and fellowships, lectures, publications, prizes, exhibitions, and public education.

    Geoffrey R. Oxnard, MD, and Barbara J. Gitlitz, MD, of USC Norris Comprehensive Cancer Center are co-recipients of the Cancer Community (C2) Catalyst Precision Medicine Award. The honor is presented to individuals that have significantly advanced precision medicine in oncology to bring new, more personalized tests or treatments to patients. Oxnard and Gitlitz, co-principal investigators of the Genomics of Young Lung Study (GOYL), conducted the first study of lung cancer in adolescents and young adults under the age of 40. They found that about 80 percent of the young lung cancer patients had a driver mutation treatable with available targeted therapies or precision medicine.

    Avinash Sahu, PhD, is one of three young scientists chosen by the Michelson Medical Research Foundation and the Human Vaccines Project to receive $150,000 each to explore novel approaches toward deciphering how the human immune system fights disease. Sahu, under the guidance of X. Shirley Liu, PhD, at Dana-Farber and Keith T. Flaherty, MD, at Massachusetts General Hospital, is working in cutting-edge research of artificial intelligence (AI) and immuno-oncology.

    F. Stephen Hodi, MD, and Eric P. Winer, MD, have been inducted into the 2019 class of Giants of Cancer Care® by OncLive, the official website for the Oncology Specialty Group. They are among 15 oncologists receiving the award, which recognizes individuals selected by their peers for landmark successes within the global field of oncology. Hodi was chosen in the melanoma and other skin cancers category; Winer was named for achievements in breast cancer.

    Harvey Cantor, MD, has received the 2019 Excellence in Mentoring Award from the American Association of Immunologists (AAI) in recognition of his exemplary contributions to future generations of scientists. Cantor is cited for training students and postdoctoral fellows and for his work as the director of NIH-funded postdoctoral training programs in cancer immunology and HIV-related research.

    Gordon Freeman, PhD, and another scientist, Clive Wood, PhD, were pronounced co-inventors on a series of cancer immunotherapy patents previously issued to a Japanese researcher and Japanese drug company. The U.S. District Court ruled that the patents be corrected to name Freeman and Wood as inventors.

    Jennifer Crombie, MD, and Samuel Ng, MD, PhD, were recently awarded pilot grants from the Harold and Virginia Lash Pilot Grant Fund for Lymphoma Research at Dana-Farber. Established in 2018, Crombie and Ng are the first recipients of these philanthropic funds, given to seed novel studies in lymphoma.

    Scott Armstrong, MD, PhD, has been selected to receive the 2019 International Society for Stem Cell Research (ISSCR) Tobias Award Lecture. Established in 2015, the award is supported by the Tobias Foundation and recognizes original and promising basic hematology research, as well as direct translational or clinical research related to cell therapy in hematological disorders.

    Karen Fasciano, PsyD, received the Outstanding Clinical Care Award at the 16th American Psychosocial Oncology Society (APOS) Annual Conference. The award recognizes an exceptional psychosocial oncology clinician for outstanding contributions to the field. The conference focused on the benefits of team-based interdisciplinary oncology, and how treating the whole patient enhances cancer care.

    Cigall Kadoch, PhD, is the recipient of the 2019 Martin and Rose Wachtel Cancer Research Award by the American Association for the Advancement of Science (AAAS) and Science Translational Medicine. The award, which is funded by an endowment courtesy of Martin Wachtel, honors early-career investigators who have performed outstanding work in the field of cancer research. Kadoch will receive $25,000 and is invited to present her research at the National Institutes of Health. Her essay will also be published in Science Translational Medicine.

    Joseph Mancias, MD, PhD, is one of nine recipients receiving the 2019 Damon Runyon-Rachleff Innovation Award. The Damon Runyon Cancer Research Foundation provides an initial grant of $400,000 over the course of two years to projects that “have the potential to significantly impact the prevention, diagnosis, and treatment of cancer.”

    Matthew Meyerson, MD, PhD, has been named the recipient of the 2019 Alfred G. Knudson Award in Cancer Genetics. Meyerson was honored for his work in advancing the understanding of the genetic basis of lung cancer. The Alfred G. Knudson award is one of two accolades presented annually by the National Cancer Institute (NCI).

    Stuart Orkin, MD, has been elected as a council member for the National Academy of Medicine (NAM). Founded in 1970, the NAM is one of three academies that compose the National Academies of Sciences, Engineering, and Medicine. As a council member, Orkin will help oversee the policies, procedures, funds, and activities of the Academy. He may also consult on a variety of NAM programs and be asked to serve different council-related committees.

    Geoffrey Shapiro, MD, PhD, received the Targeted Anticancer Therapies (TAT) Congress’ Cancer Drug Development Award. TAT is an international organization that is part of the European Society for Medical Oncology (ESMO). The award acknowledges the dedication and achievements of cancer drug development researchers.

    Toni Choueiri, MD, and Colleen Feltmate, MD, recently served on a four-member physician panel at Mohammed Bin Rashid University (MBRU) of Medicine and Health Sciences in Dubai focusing on career opportunities for medical students. The panel discussion enabled medical students at MBRU to learn about career choices from practicing physicians, get advice on internships, clinical observerships, and research opportunities, and network with panel members.

    James M. Cleary, MD, PhD, and Alan D. D’Andrea, MD, are one of seven research teams participating in the first round of the Pancreatic Cancer Collective’s “New Therapies Challenge.” An initiative of the Lustgarten Foundation and Stand Up To Cancer, the collective aims to improve pancreatic cancer patient outcomes. They collaborate to advance its diagnosis and treatment, and to support the field’s next investigators.

    January – March 2019

    The Institute

    The National Cancer Institute (NCI) has extended funding to Dana-Farber and the Broad Institute of MIT and Harvard to generate new models of cancer that more accurately represent human tumors. Dana-Farber and the Broad will serve as one of only two national Cancer Model Development Centers (CMDC) for cell line model generation as part of the NCI Human Cancer Models Initiative (HCMI). The new contract provides an additional $3,384,000 to create patient-derived cell line models of cancer for another 18 months, until May 2020, bringing the total funding for this project to $7,351,000.

    Boston Magazine has named more than 115 physicians and surgeons affiliated with Dana-Farber to its annual "Top Doctors" guide.

    The Chan Zuckerberg Initiative (CZI), in collaboration with the Human Cell Atlas (HCA), has selected Dana-Farber to be a member of their Seed Network. The Institute will join the three-year international effort to create a comprehensive reference map for all human cells.


    Eric Fischer, PhD, of the Department of Cancer Biology; Cigall Kadoch, PhD, of the Department of Pediatric Oncology; and Andrew Lane, MD, PhD, of the Department of Medical Oncology are recipients of The Mark Foundation’s inaugural Emerging Leader Awards. The foundation awarded a total of eight grants to promising early-career scientists. The awards fund high-risk, high-reward projects to address unmet needs in cancer risk, prediction, prevention, detection, and treatment. Founded in 2017 by Alex Knaster, The Mark Foundation for Cancer Research is dedicated to accelerating cures for cancer by using a high-impact approach to funding global groundbreaking research. The goal of the foundation, named in honor of Knaster’s late father, Mark, who succumbed to cancer, is to reward cutting-edge and innovative scientific ideas that attempt to answer the most complex questions about cancer biology.

    Xihao (Sherlock) Hu, PhD, is one of four 2019 Parker Scholars selected by the Parker Institute for Cancer Immunotherapy. The recognition is for early career researchers, graduate students, or researchers entering their first postdoctoral appointment. The scholars focus on novel projects that answer the most critical research questions in cancer immunotherapy. The Parker Institute for Cancer Immunotherapy was established in 2016 by the Parker Foundation to unite the country’s leading immunologists at top cancer research institutions nationwide.

    Charlotta Lindvall, MD, PhD, of Psychosocial Oncology and Palliative Care has been named a 2018 Sojourns Scholar. The Sojourns Scholar Leadership Program is an initiative led by Cambia Health Foundation that identifies and cultivates the next generation of multidisciplinary palliative care leaders, including nurses, physicians, psychologists, social workers and pharmacists, among others. Lindvall will receive a grant of $180,000 across two years to fund palliative care research projects, supporting her growth as a national leader in the field.

    Kathleen Xie, PhD, a postdoctoral fellow in the laboratory of David Pellman, MD, has received a research fellowship from the Helen Hay Whitney Foundation. The fellowship, which runs for three years, will support her research into how nuclear atypia – the presence of abnormal nuclei in cancer cells – disrupts gene activity. The Helen Hay Whitney Foundation was established in 1947 and aims to increase the number of imaginative, well-trained, and dedicated medical scientists. It awards approximately 24 research fellowships annually, for a total of more than 1,100 since its inception.

    An international team of investigators led by Wendy Garrett, MD, PhD, and Matthew Meyerson, MD, PhD, has won a Grand Challenge award from Cancer Research UK to tackle the complex issues of how the intestinal microbiome – the mix of helpful and harmful micro-organisms that reside in the colon – influence colorectal cancer development and treatment. Other Dana-Farber members of the team are Marios Giannakis, MD, PhD; Kimmie Ng, MD, MPH; and Shuji Ogino, MD, PhD. The team will receive up to $25 million (20 million British pounds) over five years from the publicly funded research and awareness charity based in the United Kingdom. The organization’s Grand Challenge awards fund “international, multidisciplinary teams willing to take on the toughest challenges in cancer.”

    Michael Constantine, MD, has been named president of the Massachusetts Society of Clinical Oncologists (MSCO). Founded in 1985, the society assists physicians with their oncology practices including: research grants, educational seminars, and access to an extensive resource library. Prior to assuming this role, Constantine served as MSCO’s treasurer.

    Catherine Hulme-Freudenberger, RN, OCN, has been recognized with a DAISY award, a quarterly honor given to an extraordinary member of the nursing department. Hulme-Freudenberger has been an infusion nurse at Milford for more than 10 years, and a member of the Integrative Nursing team for the past three years. The DAISY Foundation (Diseases Attacking the Immune System) established the award in memory of J. Patrick Barnes, whose parents create the foundation in Patrick’s memory after experiencing firsthand the skills, care, and compassion of nurses.

    Bruce Johnson, MD, chief clinical officer at Dana-Farber and director of the Center for Cancer Precision Medicine, has been named a co-principal investigator for a five-year grant awarded by the National Cancer Institute (NCI) Human Tumor Atlas Network (HTAN). The NCI HTAN grant – $12.5 million over five years – will be used to create comprehensive atlases of the molecular and cellular geography that exist in different cancers, identifying altered cells with pre-malignancy state or tumors that are treatment-resistant. This information will help identify patients who are at-risk for becoming resistant to their existing cancer therapies and develop new treatment options for them resulting in bench to bedside translational care.

    Joseph Mancias, MD, PhD, has been named one of nine 2019 recipients of the Damon Runyon-Rachleff Innovation Award. The award funds cancer research by exceptionally creative thinkers with “high-risk/high-reward” ideas who lack sufficient preliminary data to obtain traditional funding. Only those scientists with a clear vision and passion for cancer research are selected to receive the prestigious award.

    Geoffrey Shapiro, MD, PhD, Institute physician, has been given the TAT 2019 Honorary Award for cancer drug development for his leadership in developmental therapeutics, particularly in solid tumors. The TAT Honorary Award was established to acknowledge distinguished career drug development experts who have devoted a major part of their careers to the discovery and development of better anticancer medicines.

    Elizabeth Stover, MD, PhD, medical oncologist in the Division of Gynecologic Oncology, is a 2019 recipient of the Liz Tilberis Early Career Award from the Ovarian Cancer Research Alliance (OCRA). The award is for junior faculty with a strong commitment to an investigative career in ovarian cancer research. Each grantee will receive a three-year grant of $150,000 per year.

    Philippe Armand, MD, PhD, director of clinical research of the Lymphoma Program, and Lakshmi Nayak, MD, director of the Center for Central Nervous System Lymphoma, have received grants from the Leukemia and Lymphoma Society (LLS). The funding is part of the society’s $42 million commitment to advance new blood cancer treatment approaches including immunotherapy, genomics, and precision medicine.

    Jennifer Crombie, MD, and Samuel Yao-Ming Ng, MD, PhD, were awarded pilot grants in lymphoma.

    Benjamin Ebert, MD, PhD, and Matthew Meyerson, MD, PhD, were elected to the National Academy of Medicine in recognition of their outstanding professional achievement and commitment to service. It is one of the highest honors in the health and medicine fields, and Ebert and Meyerson are two of 85 newly elected members.

    Sarah Hill, MD, PhD, Divya Iyer, PhD, and Issac Klein, MD, PhD, are recipients of the Ann and Sol Schreiber Mentored Investigator Award from the Ovarian Cancer Research Alliance (OCRA). The Award provides a total of $75,000 to be used over one or two years and will encourage the recipient’s research career in the field of ovarian cancer.

    Nina Ilic, PhD, Oliver Jonas, PhD, Elizabeth Stover, MD, PhD, and Adam Sperling, MD, PhD, are four Dana-Farber scientists pursuing research funded by the 2019 endowed Wong Family Awards in Translational Oncology, which support translational oncology and biotechnology development at the Institute. Aiming to make personalize medicine a reality for all patients, the awards recognize “the most meritorious, innovative, translational projects that utilize information from multiple platforms to develop new diagnostics, prognostic markers, predictive markers, or therapeutics for cancer.” The Wong Family Awards program began in 2012, and the endowment provides a distribution that funds the awards annually; the amount for 2019 is $300,000.

    October – December 2018

    The Institute

    Dana-Farber Cancer Institute and Deerfield Management announced an up to $80 million collaboration to create the Center for Protein Degradation at Dana-Farber. The goal of the Center for Protein Degradation is to interrogate and advance a large portfolio of advanced targeted protein degrader targets while creating a next-generation protein degrader platform. The new Center for Protein Degradation will be led by Nathanael Gray, PhD, and Eric Fischer, PhD, while operational support, management expertise, and initial funds will be contributed by Deerfield.

    The Pan-Mass Challenge (PMC) announced an unprecedented $56 million gift to Dana-Farber Cancer Institute – exceeding last year’s contribution by a staggering $5 million.


    Pasi Jänne, MD, PhD, received an Outstanding Investigator Award from the National Cancer Institute (NCI). Up to $600,000 in direct costs per year for seven years is provided to investigators to work on projects of unusual potential. Award recipients are cancer researchers who have been nominated by their institutions, have served as a principal investigator on an NCI grant for the last five years, and have demonstrated outstanding research.

    Justin Kim, PhD, received the 2018 National Institutes of Health (NIH) Director’s New Innovator Award. Established in 2007, the NIH Director’s New Innovator Award supports unusually innovative research from early career investigators within 10 years of their final degree or clinical residency who have not yet received a research project grant or equivalent NIH grant. Kim, among 58 other highly distinguished innovative scientists, will receive funding to further his impact on, and address challenges in relation to, biomedical science.

    Eric P. Winer, MD, has received the Susan G. Komen Foundation’s 2018 Brinker Award for Clinical Distinction in Clinical Research. Winer was honored for his seminal contributions in improving breast cancer treatments, which have helped shape the standard of care for breast cancer patients globally.

    Susan Bullman, PhD, and Shekinah Elmore, MD, MPH, have been named as 2018 STAT Wunderkinds. STAT Wunderkinds searches for the most impressive young doctors and researchers in the fields of health and medicine in North America.

    Pasi A. Jänne, MD, PhD, received the European Society for Medical Oncology (ESMO) Award for Translational Research. ESMO is the leading organization for medical oncology education and information committed to offering the best treatment to cancer patients. Established in 1985, the award recognizes excellence in medical oncology advancements within the European and international community and was presented to Jänne for his novel therapeutic agents in patients with lung cancer.

    Giovanni Parmigiani, PhD, was awarded the distinction of Fellow by the American Association for the Advancement of Science (AAAS). Parmigiani, among other individuals, has been elevated to this rank because of his efforts toward advancing science applications that are deemed scientifically or socially distinguished.

    David Weinstock, MD, has been named a 2018 Allen Distinguished Investigator by the Allen Institute. The Allen Distinguished Investigator program funds early stage research that is less likely to receive support from traditional funding sources but has the potential to significantly advance the understanding of biology. Weinstock, who shares the award with Scott Manalis, PhD, of MIT is studying why some lymphoma patients are cured but others relapse.

    David A. Williams, MD, was awarded the 2018 Karl Landsteiner Memorial Award and Lectureship. Initiated in 1954 to honor the late Karl Landsteiner, the distinction is awarded annually by the American Association of Blood Banks (AABB) to a scientist whose work has profoundly influenced the fields of transfusion medicine and cellular therapies. Williams was recognized for his work on hematopoietic stem cells and how their interaction with bone marrow can play a role in stem cell engraftment and mobilization.

    William G. Kaelin Jr., MD, received the 2018 Massry Prize and will share the $200,000 award with two other scientists, in addition to receiving a 10-ounce gold medal, for outstanding contributions to the biomedical sciences and the advancement of health. The three researchers were cited for the discovery of the pathway by which cells from humans and most animals sense and adapt to changes in oxygen availability.

    May – September 2018

    The Institute

    Members of Dana-Farber’s Legislative Action Network (LAN) played a role in the recent passage of a state law raising the age limit for purchasing tobacco products from 18 to 21.

    Dana-Farber faculty, patients, family members, and staff have been active in the coalition of the passing of the Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act. As the most comprehensive childhood cancer bill ever taken up by Congress, expanded research opportunities may improve efforts to track the disease across populations, and improve the quality of life for pediatric cancer survivors.

    Dana-Farber/Brigham and Women's Cancer Center was ranked the highest for cancer care in New England for the 18th straight year, by U.S. News & World Report. This year, Dana-Farber/Brigham and Women’s Cancer Center was ranked #4 in the nation.

    Dana-Farber was ranked #7 on Forbes 2018's “America’s Best Mid-Size Employers” list.

    Dana-Farber/Boston Children's Cancer and Blood Disorders Center was named the top pediatric cancer program in New England and #3 in the nation by U.S. News & World Report in its new 2018-19 Best Children's Hospitals report.


    Matthew S. Davids, MD, of Medical Oncology, received the first James O. Armitage Lymphoma Clinical Investigator Award at the Pan Pacific Lymphoma Conference. The conference is one of the largest gatherings of experts in lymphoma and transplantation. This award acknowledges a clinical investigator whose research shows promise and clinical applicability in the area of lymphoma.

    Eliezer Van Allen, MD, of Medical Oncology, has been awarded a Continuation Grant from the Damon Runyon Cancer Research Foundation. The Continuation Grant provides two additional years of support to Damon Runyon Clinical Investigators in need of additional time and funding for their research. The $300,000 grant is given over a period of two years.

    Benjamin Izar, MD, PhD, has received a Career Award for Medical Scientists from the Burroughs Wellcome Fund. The $700,000 award, given over five years, will support Izar’s research on understanding mechanisms conferring resistance to immune checkpoint inhibitors.

    Caron A. Jacobson, MD, MMS, received a 2018 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI). The award is given to outstanding mid-career clinical investigators at NCI-Designated Cancer Centers (of which Dana-Farber/Harvard Cancer Center (DF/HCC) is one) in recognition of their extensive involvement in NCI-funded collaborative clinical trials.

    Cigall Kadoch, PhD, and Paige Malinowski, manager of Dana-Farber's Young Adult Program, were recently named among the nation’s top “40 Under 40 in Cancer” by The Lynx Group and McGivney Global Advisors. The inaugural award celebrates the contributions individuals under age 40 make to improve the lives of those affected by cancer.

    Nancy Lin, MD, of Medical Oncology and Jean Zhao, PhD, of Dana-Farber's Department of Cancer Biology have received a Breakthrough Award from the U.S. Department of Defense to do preclinical testing of drugs known as CDK4/6 inhibitors for breast cancer that has metastasized to the brain. The research builds on Zhao and her colleagues discovery that the CDK4/6 protein is often deregulated in HER2-positive breast cancer that has spread to the brain.

    Alexandre Detappe, PhD, is one of five young cancer researchers selected to receive a Multiple Myeloma Research Foundation (MMRF) Research Fellow Award. Detappe, a postdoctoral research fellow, is currently focused on “Nanoparticle for Early Detection of Minimal Residual Disease in Multiple Myeloma.”

    Lisa R. Diller, MD, has been named a fellow at the Radcliffe Institute for Advanced Study at Harvard University. Each year, the Radcliffe Institute for Advanced Study supports the work of 50 fellows in the arts, humanities, sciences, and social sciences. Diller will be the 2018-2019 Lillian Gollay Knafel Fellow at Radcliffe, and will be studying the clinical impact of genetic information associated with increased cancer risk in children.

    G. Mike Makrigiorgos, PhD, has received two federal grants totaling nearly $3 million for collaborative research aimed at detecting “needle-in-a-haystack” mutations circulating in the blood of cancer patients. Both grants from the National Institutes of Health (NIH) support innovative methods to boost the detection of tumor DNA in liquid biopsies.

    Stuart H. Orkin, MD, has been selected as the recipient of the 2018 Mechthild Esser Nemmers Prize in Medical Science at Northwestern University. This Nemmers Prize is awarded for achievement and work of lasting significance in the field of medical science. The prize recognizes major contributions to new knowledge or the development of significant new modes of analysis.

    Xiao X. Wei, MD, has received a Young Investigator Award from the Kidney Cancer Association. The one-year grant of $50,000 will help fund urology and clinical oncology research, in line with the Kidney Cancer Association’s goal of improving the lives of those who have been, and will be, diagnosed with kidney cancer.

    Judy E. Garber, MD, MPH, and Bruce Johnson, MD, are among 21 inductees of the 2018 Giants of Cancer Care recognition program. Respected health care professionals were awarded for advancing the field of oncology for their contributions in research and clinical practice.

    Lillian M. Guenther, MD, MPH, David Liu, MD, and Harshabad Singh, MD, were three of only five doctors across the country to receive a 2018 Damon Runyon Cancer Research Foundation Physician-Scientist Training Award. The award supports early career physician-scientists by incentivizing an academic research career with a significant four-year grant for a mentored research project.

    Patrick Ott, MD, PhD, Osama Rahma, MD, Catherine Wu, MD, and Bradley Pentelute, PhD, of the Massachusetts Institute of Technology, have received a Team Science Award from the Melanoma Research Alliance (MRA). The three-year grant, created with funding from BJ’s Wholesale Club, will support their research into next-generation neoantigen-targeting peptide vaccines for melanoma patients.

    Benjamin Ebert, MD, PhD, has been chosen to join the elite cadre of biomedical scientists chosen by the Howard Hughes Medical Institute (HHMI) to receive long-term, flexible funding as an HHMI Investigator. Ebert is one of 19 new investigators, chosen from 675 eligible applicants, whose selection was recently announced. Each investigator will receive approximately $8 million over a seven-year term that is renewable pending a scientific review. The new group of investigators is the first to be appointed to a seven-year term – previously it was five years.

    Laurie H. Glimcher, MD, president and CEO of Dana-Farber, has received a Lifetime Achievement Award from the American Association of Immunologists (AAI). The award is presented in recognition of a remarkable career of scientific achievement and contributions to the AAI and the field of immunology.

    Shom Goel, MD, PhD, has been awarded a Komen Career Catalyst Research Grant to investigate strategies for overcoming drug resistance in breast cancer treatment. The $450,000 grant from Susan G. Komen® will be used to research why estrogen receptor positive (ER-positive) breast cancers become resistant to drugs known as CDK4/6 inhibitors that are initially effective against the tumors.

    Irene Ghobrial, MD, co-leader of a Stand Up To Cancer (SU2C) Dream Team, was awarded $10 million for a novel project aimed at detecting individuals with precursor conditions before they develop full-blown multiple myeloma, an incurable blood cancer.

    Jennifer Guerriero, PhD, has been awarded a Komen Career Catalyst Research Grant to study drug resistance in triple-negative breast cancer.

    Pasi A. Jänne, MD, PhD, is the 2018 recipient of the Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research from the American Association for Cancer Research (AACR). The award, named for one of the country’s leading experts in head and neck and lung cancer, recognizes worthy cancer researchers, age 51 and under, who have conducted highly meritorious translational and clinical cancer research.

    Christopher J. Recklitis, PhD, MPH, has received a SunSmart: Preventing Secondary Skin Cancer in Young Adult Cancer Survivors Award from the Prevent Cancer Foundation. Funding from the award will enable him and his colleagues to refine and test SunSmart, a video they produced to prevent skin cancer in young adult survivors of cancer by encouraging proper sun protection.

    Michal Sheffer, PhD, has won a Stand Up To Cancer (SU2C) Phillip A. Sharp Innovation in Collaboration Award. Sheffer will work with the University Medical Center Utrecht in the Netherlands and young investigator on the SU2C-Dutch Cancer Society Tumor Organoids Dream Team. Their project focuses on studies of colorectal cancer patient-derived organoids to validate candidate biomarkers of resistance to natural killer cells.

    Several Dana-Farber physicians and researchers received awards or were elected to leadership positions during the annual meeting of the American Association for Cancer Research (AACR):

    • Institute President and CEO, Laurie H. Glimcher, MD, was elected a Fellow of the AACR Academy, Class of 2018. The AACR Academy recognizes distinguished scientists whose major contributions have propelled significant innovation and progress against cancer.
    • Judy E. Garber, MD, MPH, was elected to serve on the AACR Nominating Committee for the 2018-2020 term. She was also elected by her colleagues in the AACR Academy to serve as inaugural AACR Academy President-Elect.
    • Utthara Nayar, PhD, a research fellow in the laboratory of Nikhil Wagle, MD, received the prestigious AACR Women in Cancer Research Scholar Award.

    Twenty-seven Dana-Farber nurses were recognized in the Boston Globe’s annual “Salute to Nurses” supplement, which ran in conjunction with National Nurses Week. The honorees include:

    • Paula Buckley
    • Cindy Cao
    • Carla Chapman
    • Virginia Dalton
    • Erin Drury
    • Lauren Engel
    • Katherine Fleming
    • Brittney Fontana
    • Karen Francour
    • Kristen Graham
    • Anne Gray
    • Jillian Hoffman
    • Kathy Houlahan
    • Elizabeth Llewellyn
    • Jennifer Lowell
    • Jen McKenna
    • Elizabeth Newins
    • Suzanne Oliver
    • Courtney Shea
    • Robin Sommers
    • Despina Stavros
    • Kate Stephans
    • Ann Stewart
    • Jackie Tuskan
    • Meghara Walsh
    • Annette Werger
    • Alyssa Ywuc

    2018 Nursing and Patient Care Services (NPCS) Award recipients include:

    • Kathleen Bieglagus, BSN, RN, who was presented with the Thomas M. Kloss Nursing Leadership Award, which recognizes a nurse whose work promotes and fosters the Institute’s mission and core values.
    • Janette Danowski Hale, RPh, BCOP, who was presented with the Clinician Collaborator in Care Award, which recognizes a non-NPCS clinician who has demonstrated ongoing, consistent support and appreciation for the contribution of nursing and patient care services in overall achievement of quality patient outcomes over the past year.
    • Amy Ferreira, Damon Morris, and Lindsay Speight, who were presented with the Outstanding Clinic Assistant Award, which recognizes clinic assistants whose practice and teamwork has been exemplary over the past year.
    • Nancy Grant, RN, OCN, who was presented with the President’s Award for Nursing Excellence, Dana-Farber’s highest nursing honor, which recognizes a DFCI nurse who demonstrates ongoing dedication and commitment to providing the highest quality oncology care to patients, families, and the community.
    • Nane Kouyoumjian and Scott Maidment, who were presented with the Cancer Care Culture of Care Award for Excellence in Patient Experience, which recognizes NPCS staff members whose work promotes and fosters the Institute’s mission and core values.
    • Jeanine McManus, BSN, RN, and Cameron Sze, BSN, RN, who were presented with the Award for Excellence in Relationship-Based Nursing Care, which recognizes exemplary relationship-based nursing care practices.

    February – April 2018

    The Institute

    Dana-Farber has been recognized for the sixth time as a 2018 leader in LGBTQ Healthcare Equality by the Human Rights Campaign Foundation. Leaders are determined through evaluation by the Healthcare Equality Index (HEI), an annual survey that measures inclusive policies and practices at more than 2,000 medical facilities nationwide.

    Dana-Farber’s blog, Insight, won the first-ever Best in Show honor in the Association of American Medical Colleges Group on Institutional Advancement Awards for Excellence competition. Insight is a hub of information and inspiration for cancer patients, their friends and families, and the general public.

    Dana-Farber’s Office of Workforce Development celebrated its 10-year anniversary, and received two citations for “promoting an inclusive workforce for advancement in the healthcare industry,” and its “commitment to the development of its current and future workforce through programs that increase access and reduce barriers to personal professional and economic development opportunities.” The two citations were sponsored by Representative Jeffrey Sanchez and Senator Sonia Chang-Diaz.


    Lakshmi Nayak, MD, director of the Central Nervous System Lymphoma Center (CNSLC) and senior physician at Dana-Farber, and an assistant professor of Neurology at Harvard Medical School, has received the 2018 Leukemia and Lymphoma Society Scholar in Clinical Research Award that supports talented blood cancer researchers in the early phase of their careers. Nayak will receive grants over a period of five years totaling $625,000.

    Rosalind A. Segal, MD, PhD, will receive the 2018 Harold Amos Faculty Diversity Award from Harvard Medical School (HMS). The Harold Amos Faculty Diversity Award was established to recognize faculty who have made significant achievements in moving HMS and the Harvard School of Dental Medicine forward in becoming a more diverse and inclusive community.

    Patrick Y. Wen, MD, director of the Center for Neuro-Oncology and Institute Physician at Dana-Farber and professor of Neurology at Harvard Medical School, was named board president of the Society for Neuro-Oncology.

    Eric Fischer, PhD, a member of Dana-Farber’s Chemical Biology Program, will receive a 2018 Damon Runyon Cancer Research Foundation Innovation Award that funds research on novel approaches to fighting cancer. Fischer is one of 10 early career scientists selected for the Damon Runyon-Rachleff Innovation Award, and will receive an initial grant of $300,000 over two years. Each awardee will have the opportunity to receive two additional years of funding at the same level.

    Myles Brown, MD, and Judy Garber, MD, MPH, have won a grant to investigate a novel strategy aimed at easing the transition to menopause for women having their ovaries removed because they carry a mutated cancer risk gene.

    Constantine Mitsiades, MD, PhD, has received a Stand Up To Cancer (SU2C) Convergence Team Translational Cancer Research Grant for collaborative studies related to cancer immunotherapy. SU2C announced a total of $11 million to seven multidisciplinary research teams to investigate immune system response to cancers.

    Myles Brown, MD, director of Dana-Farber's Center for Functional Cancer Epigenetics, is a leader of one of eight international scientific teams receiving Prostate Cancer Foundation Challenge Awards aimed at accelerating new and improved treatments for prostate cancer.

    Mary E. Cooley, PhD, RN, FAAN, has been chosen by the Oncology Nursing Society, as its first Scholar-in-Residence to work with leadership in creating a new strategic vision for the society’s research agenda.

    Lisa Scherber, director of Patient and Family Programs, was honored at the 79th annual Boston Baseball Writer's Dinner with The Sports Museum Lifetime Achievement Award – given each year to a civic or business leader connected to baseball who positively impacts the Boston community.

    Meghan Underhill-Blazey, PhD, APRN, is the recipient of the Oncology Nursing Society’s Victoria Mock New Investigator Award, which is awarded in recognition of her scientific contributions to oncology nursing. It is one of the society’s highest honors.

    Three Dana-Farber physicians from our Susan F. Smith Center for Women’s Cancers have been recognized among the top 27 breast oncologists across the country by Forbes Magazine: Harold Burstein, MD, PhD, a clinician and clinical investigator in the breast oncology center; Ann Partridge, MD, MPH, co-founder and director of the young women with breast cancer program and head of adult survivorship; and Eric P. Winer, MD, chief of the division of women’s cancers and senior vice president for medical affairs, have been selected as exemplary leaders in the field of breast oncology.

    Six Dana-Farber scientists are pursuing research funded by the 2018 endowed Wong Family Awards in Translational Oncology, which support translational oncology and biotechnology development at the Institute:

    Scott Carter, PhD, and Co-PI R. Coleman Lindsley, MD, PhD, who use cutting-edge methods to extract genotyping data from 17,000 tumor samples generated by the Profile research program.

    Andrew Hong, MD, who is harnessing a technology called MITE to characterize all the possible mutations in a cancer gene known as SMARCB1, which can cause a rare, devastating group of cancers affecting children and young adults.

    Seth Wander, MD, PhD, in collaboration with his research mentor Nikhil Wagle, MD, and the Dana-Farber Center for Cancer Precision Medicine, is investigating the molecular causes of resistance to CDK 4/6 inhibitors in patients with estrogen receptor-positive metastatic breast cancer.

    Pablo Martinez, MD, PhD, and Co-PI Chiara Ambrogio, PhD, are studying a family of proteins known as APOBEC enzymes.

    November 2017 – January 2018

    The Institute

    Boston magazine has named 79 physicians and surgeons affiliated with Dana-Farber to its annual “Top Doctors” guide. Drawing from a Castle Connolly physician database, the list consists of hundreds of Boston-area physicians from many medical specialties.

    Following a two-day site visit, surveyors from the American College of Surgeons Commission on Cancer (CoC) have recommended a full three-year re-accreditation with commendation for Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC). Commendation was given in five areas: clinical research accrual, oncology nursing care, cancer registrar education, Rapid Quality Reporting System participation, and data submission accuracy.

    Tobacco Free Mass, a coalition that has advocated for funding and policies supporting tobacco prevention and cessation for 25 years, recently honored Dana-Farber for its longtime commitment to this mission. The coalition acknowledged Dana-Farber’s “continued leadership role in the fight against tobacco and its harms.”


    Nikhil C. Munshi, MD, received an approximately $11 million grant from the National Institutes of Health (NIH) in support of his research program project, Integrative Oncogenomics of Multiple Myeloma.

    Clare Sullivan, BSN, MPH, OCN, clinical program manager of Patient Education, has been appointed to the board of the Cancer Patient Education Network (CPEN), a national interdisciplinary cancer collaborative founded by the National Cancer Institute (NCI) to strengthen the role of patient education in cancer care.

    Gregory Abel, MD, MPH, and R. Coleman Lindsley, MD, PhD, have received two of the inaugural research grants from the Dresner Foundation’s Myelodysplastic Syndrome (MDS) Research Fund. The awards support cutting-edge MDS research and related programs to improve future standards of care and ultimately lead to a cure.

    Amanda Balboni Iniguez, PhD, a postdoctoral fellow at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, has received the Damon Runyon-Jake Wetchler Award for Pediatric Innovation for her work studying mechanisms of drug resistance in childhood neuroblastoma.

    Paul Nuccio, RRT, FAARC, director of pulmonary services at Brigham and Women’s Hospital and Dana-Farber, received a Lifetime Achievement Award for his years of service to the respiratory therapy profession. Nuccio received the award at the annual meeting of the Massachusetts Society for Respiratory Care.

    Heather Parsons, MD, MPH, has been awarded a three-year postdoctoral fellowship to identify, through changes in circulating tumor DNA, causes of treatment resistance in patients with HER2-positive metastatic breast cancer. Her research is supported by a grant from Susan G. Komen®.

    Ann Partridge, MD, MPH, received the 2017 Edward J. Benz Jr. Award for Advancing the Careers of Women Faculty. The award, previously known as the Advancing the Careers of Women Faculty Award, was announced by the Office for Faculty Development and Committee for Women Faculty. It was renamed in 2017 to honor the legacy of the former Dana-Farber president and CEO.

    Stephen Sallan, MD, received Camp Casco’s first-ever Friend for Life Award during its annual benefit event. The award is given to an outstanding individual whose efforts have deeply impacted the childhood cancer community. Sallan was recognized for his work in progressing the treatment of acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer.

    Andrew Aguirre, MD, PhD, and Andrew Lane, MD, PhD, both of Medical Oncology, are among this year’s recipients of Clinical Scientist Development Awards from the Doris Duke Charitable Foundation. The awards, which provide $495,000 in research support over three years, are presented to junior scientists who have distinguished themselves by the rigor of their research and their commitment to future excellence as independent clinical researchers.

    Institute scientists were among the recipients of the first Xconomy Awards, honoring people who lead innovation in the Boston life sciences community. David Livingston, MD, in collaboration with MIT, was the winner of the Xconomy Big Idea Award was the Bridge Project, which fosters collaboration between cancer researchers from MIT and Harvard-affiliated hospitals and schools in addressing challenging problems in cancer research and care. The recipient of the Xconomy Award in Patient Partnership was Dana-Farber’s Nikhil Wagle, MD, for his work in creating the Metastatic Breast Cancer Project, which collects and sequences DNA from patients’ tumors and looks for genetic changes that are associated with patients’ response, or lack of response, to treatment.

    Dana-Farber Cancer Institute President and CEO, Laurie H. Glimcher, MD, was honored by the AAMC (Association of American Medical Colleges) with the prestigious Award for Distinguished Research in the Biomedical Sciences at a special presentation during the AAMC annual meeting in Boston. The AAMC cited her numerous discoveries that have advanced treatments for several diseases and chronic conditions, including cancer, asthma, and osteoporosis.

    George Canellos, MD, received a Hope Funds for Cancer Research Award of Excellence in Medicine. The award recognizes outstanding achievements in the fields of basic research, drug development, medicine, patient support, and philanthropy. Canellos was honored for his work in the development of combination chemotherapy regimens, including one of the first such regimens for breast cancer and one for lymphoma.

    William Hahn, MD, PhD, participated in a panel discussion on “The War on Cancer 3.0” as part of the HUBweek Festival. The event provided a forum for Hahn and other prominent cancer researchers to explore the future of cancer treatment.

    Christopher Lathan, MD, MS, MPH, has been recognized as one of 57 local leaders of color in the life sciences and health care sectors. The list was compiled by Get Konnected, a group launched by Colette Phillips, who runs a communications and marketing firm in Boston.

    Patrick Wen, MD, has been elected president of the Society for Neuro-Oncology (SNO). The society is the premier North American organization for clinicians, basic scientists, nurses, and other health care professionals focusing on central nervous system tumors in children and adults. Mark Kieran, MD, PhD, will become the pediatric representative to the SNO board, and Ian Dunn, MD, will be the neurosurgical representative. The newly elected members will assume their positions following the SNO annual meeting later this month.